Alkaloid derivative ION-31a inhibits breast cancer metastasis and angiogenesis by targeting HSP90α

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer is a leading cause of death in women.
• Previous research identified ION-31a, an ionone alkaloid derivative, with potential anti-metastasis activity.
• Identifying the specific therapeutic target of ION-31a is crucial for its drug development.

Purpose of the Study:

• To identify the molecular target of the anti-cancer compound ION-31a.
• To elucidate the mechanism of action of ION-31a in suppressing breast cancer metastasis.
• To evaluate the therapeutic potential of ION-31a as an anti-metastatic agent.

Main Methods:

• Utilized a fluorescence-tagged probe for target identification.
• Employed molecular docking simulations to predict binding interactions.
• Conducted surface plasmon resonance (SPR) analysis to confirm target engagement.
• Investigated the inhibition of key signaling pathways in vitro and in vivo.

Main Results:

• Identified heat shock protein 90 (HSP90) as the primary molecular target of ION-31a.
• ION-31a functions as a novel HSP90 inhibitor, significantly suppressing breast cancer metastasis and angiogenesis.
• ION-31a inhibits the HSP90/hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) pathway.
• Downstream signaling pathways, including AKT/mTOR, AKT2/PKCζ, ERK1/2, FAK, and p38MAPK, are negatively regulated by ION-31a.

Conclusions:

• ION-31a is a novel HSP90 inhibitor with significant anti-metastatic and anti-angiogenic properties against breast cancer.
• The compound effectively targets multiple pathways involved in tumor progression and metastasis.
• ION-31a demonstrates potential for development as a therapeutic agent for treating metastatic breast cancer.